Putnam FL Investment Management Co. boosted its stake in Eli Lilly and Company (NYSE:LLY) by 37.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 21,076 shares of the company’s stock after buying an additional 5,778 shares during the period. Putnam FL Investment Management Co.’s holdings in Eli Lilly and were worth $1,773,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sunbelt Securities Inc. raised its stake in shares of Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock worth $313,000 after buying an additional 17 shares during the last quarter. Northwest Quadrant Wealth Management LLC raised its stake in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after buying an additional 19 shares during the last quarter. Pillar Pacific Capital Management LLC raised its stake in shares of Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock worth $595,000 after buying an additional 20 shares during the last quarter. Rehmann Capital Advisory Group raised its stake in shares of Eli Lilly and by 0.9% in the first quarter. Rehmann Capital Advisory Group now owns 5,026 shares of the company’s stock worth $423,000 after buying an additional 43 shares during the last quarter. Finally, Joel Isaacson & Co. LLC raised its stake in shares of Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 75.77% of the company’s stock.

Eli Lilly and Company (LLY) traded down 0.171% during trading on Tuesday, hitting $78.705. The stock had a trading volume of 439,661 shares. The stock has a market capitalization of $83.03 billion, a PE ratio of 34.057 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock’s 50-day moving average is $81.83 and its 200-day moving average is $81.93.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the company posted $0.86 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.64%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/29/eli-lilly-and-company-lly-stake-increased-by-putnam-fl-investment-management-co.html.

LLY has been the subject of a number of research analyst reports. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a research note on Tuesday, May 16th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, May 30th. Oppenheimer Holdings, Inc. lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target for the company. in a research note on Wednesday, July 26th. Finally, TheStreet lowered Eli Lilly and from a “b+” rating to a “c” rating in a research note on Wednesday, May 31st. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $87.92.

In related news, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock worth $55,845,287 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.